Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedApr 15, 2026
DataAggregated Company Financials
Companies147
  • 7D6.1%
  • 3M-0.2%
  • 1Y7.6%
  • YTD2.6%

In the last week, the Healthcare industry is up 6.1%, with Camurus leading the way with a 8.9% gain. In the last 12 months, the industry was up 7.6%. Looking forward, earnings are forecast to grow by 24% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 15 Apr 2026SEK 599.4bSEK 228.7b-SEK 2,934,568,897.9534.5x-204.2x2.6x
Fri, 13 Mar 2026SEK 554.3bSEK 228.8b-SEK 2,920,410,848.9530.1x-189.8x2.4x
Sun, 08 Feb 2026SEK 582.6bSEK 229.3b-SEK 1,816,881,182.0734x-320.6x2.5x
Tue, 06 Jan 2026SEK 578.8bSEK 230.3bSEK 3.7b40.7x157.6x2.5x
Thu, 04 Dec 2025SEK 588.0bSEK 230.7bSEK 3.6b42.1x164x2.5x
Sat, 01 Nov 2025SEK 610.3bSEK 228.3bSEK 3.3b46.3x183.4x2.7x
Mon, 29 Sep 2025SEK 593.6bSEK 227.1bSEK 6.6b43.5x89.8x2.6x
Wed, 27 Aug 2025SEK 629.5bSEK 227.3bSEK 6.5b47.3x97.6x2.8x
Fri, 25 Jul 2025SEK 638.2bSEK 226.0bSEK 6.4b50.5x99.3x2.8x
Sun, 22 Jun 2025SEK 593.9bSEK 226.9bSEK 5.9b45x101.4x2.6x
Tue, 20 May 2025SEK 610.5bSEK 224.9bSEK 5.6b43.9x109.3x2.7x
Thu, 17 Apr 2025SEK 547.4bSEK 221.8bSEK 5.5b32.7x99.6x2.5x
Sat, 15 Mar 2025SEK 558.6bSEK 206.4bSEK 4.9b37.2x114x2.7x
Mon, 10 Feb 2025SEK 600.9bSEK 220.4bSEK 2.5b42x238.4x2.7x
Wed, 08 Jan 2025SEK 585.5bSEK 202.7b-SEK 2,498,966,853.1541.3x-234.3x2.9x
Fri, 06 Dec 2024SEK 567.9bSEK 202.5b-SEK 2,446,380,573.0937.8x-232.2x2.8x
Sun, 03 Nov 2024SEK 524.9bSEK 200.0b-SEK 2,887,185,216.9836.7x-181.8x2.6x
Tue, 01 Oct 2024SEK 624.6bSEK 200.0b-SEK 2,815,788,245.8340.7x-221.8x3.1x
Thu, 29 Aug 2024SEK 605.4bSEK 199.9b-SEK 2,307,475,072.1639.5x-262.4x3x
Sat, 27 Jul 2024SEK 593.0bSEK 200.1b-SEK 2,851,179,974.0841.4x-208x3x
Mon, 24 Jun 2024SEK 557.3bSEK 195.5b-SEK 3,182,934,253.1735.3x-175.1x2.9x
Wed, 22 May 2024SEK 549.7bSEK 196.2b-SEK 2,898,290,123.2937.1x-189.7x2.8x
Fri, 19 Apr 2024SEK 509.0bSEK 193.2b-SEK 3,150,066,827.0144.5x-161.6x2.6x
Sun, 17 Mar 2024SEK 521.7bSEK 192.3b-SEK 3,668,536,869.5343.5x-142.2x2.7x
Tue, 13 Feb 2024SEK 509.4bSEK 191.0b-SEK 4,141,571,119.4747.8x-123x2.7x
Thu, 11 Jan 2024SEK 551.5bSEK 191.4b-SEK 963,622,982.0047.7x-572.3x2.9x
Sat, 09 Dec 2023SEK 506.7bSEK 190.4b-SEK 1,067,979,885.0051.2x-474.4x2.7x
Mon, 06 Nov 2023SEK 458.1bSEK 190.0b-SEK 1,067,305,617.0040.3x-429.2x2.4x
Wed, 04 Oct 2023SEK 450.0bSEK 185.1b-SEK 2,029,179,031.0034.9x-221.8x2.4x
Fri, 01 Sep 2023SEK 467.2bSEK 185.5b-SEK 2,091,654,234.0038x-223.4x2.5x
Sun, 30 Jul 2023SEK 478.9bSEK 183.8b-SEK 984,749,071.0040.3x-486.3x2.6x
Tue, 27 Jun 2023SEK 474.2bSEK 179.1b-SEK 798,980,189.0043.4x-593.6x2.6x
Thu, 25 May 2023SEK 512.8bSEK 177.7b-SEK 804,181,914.0041.8x-637.6x2.9x
Sat, 22 Apr 2023SEK 511.2bSEK 173.1b-SEK 1,502,209,816.0035x-340.3x3x
Price to Earnings Ratio

-340.3x


Total Market Cap: SEK 511.2bTotal Earnings: -SEK 1,502,209,816.00Total Revenue: SEK 173.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -162x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 9.7% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market5.71%
Healthcare6.07%
Pharma9.75%
Life Sciences9.44%
Biotech6.17%
Healthtech6.04%
Healthcare Services5.74%
Medical Equipment4.30%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 117x.
    • Analysts are expecting annual earnings growth of 20.2%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 19% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CAMX CamurusSEK 539.508.9%
+SEK 2.6b		-4.1%PE43.8x
SECT B SectraSEK 254.405.2%
+SEK 2.4b		-7.3%PE91.2x
ASKER Asker Healthcare GroupSEK 76.008.2%
+SEK 2.2b		-0.9%PE63.1x
BONEX Bonesupport HoldingSEK 258.6012.7%
+SEK 1.9b		-18.5%PE121.5x
SOBI Swedish Orphan BiovitrumSEK 412.001.3%
+SEK 1.8b		57.0%PE297.9x

Latest News

CARA
SEK 22.80
Carasent
7D
-4.2%
1Y
-1.0%
GETI B
SEK 199.65
Getinge
7D
3.0%
1Y
1.9%
CAMX
SEK 539.50
Camurus
7D
8.9%
1Y
-4.1%

CAMX: 2026 Earnings Guidance Will Support Further Share Price Upside

Analysts have maintained their SEK 930 price target on Camurus, supported by updated forecasts that reflect slightly higher revenue growth, a marginally stronger profit margin, and a modestly lower future P/E assumption. What's in the News Camurus issued earnings guidance for 2026, with expected revenues in a range of SEK 2.6b to SEK 2.9b.
VITR
SEK 106.50
Vitrolife
7D
11.8%
1Y
-31.2%

VITR: Governance Amendments And Steady Assumptions Will Support Future Upside

Analysts have reduced their price target for Vitrolife to SEK 163.40 from SEK 176.75, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News Vitrolife AB (publ) has proposed amendments to its Articles of Association to be decided at the Annual General Meeting scheduled for May 5, 2026.
OSSD
SEK 4.09
OssDsign
7D
-30.4%
1Y
-71.4%
SOBI
SEK 412.00
Swedish Orphan Biovitrum
7D
1.3%
1Y
57.0%
ALIF B
SEK 159.60
AddLife
7D
8.7%
1Y
2.7%

ALIF B: Higher Margins And Dividend Outlook Will Support Future Upside

Analysts have maintained their SEK 187.50 price target on AddLife, with updated assumptions around discount rate, revenue growth, profit margin and future P/E that now reflect a slightly different balance of risk, earnings potential and valuation multiples. What's in the News AddLife AB (publ) announced an annual dividend of SEK 1.50 per share, with ex date on May 7, 2026, record date on May 8, 2026, and payment on May 13, 2026 (Key Developments).
BONEX
SEK 258.60
Bonesupport Holding
7D
12.7%
1Y
-18.5%
SECT B
SEK 254.40
Sectra
7D
5.2%
1Y
-7.3%

SECT B: Cloud Contracts And Rating Upgrades Will Shape Future Return Balance

Analysts have maintained the fair value estimate for Sectra at SEK 227.50. Recent upgrades and new price targets, which range from SEK 210 to SEK 250, support a slightly lower implied discount rate and marginally adjusted long-term growth and P/E assumptions.
STIL
SEK 215.00
Stille
7D
-5.3%
1Y
0.9%
HNSA
SEK 29.26
Hansa Biopharma
7D
-5.1%
1Y
36.0%

HNSA: U.S. Kidney Transplant Approval Pathway Will Drive Potential Upside

Analysts have adjusted their price target on Hansa Biopharma by SEK 8, reflecting updated views on the risk profile and near term commercial opportunity for imlifidase, including its potential positioning in kidney transplantation and autoimmune indications. Analyst Commentary Recent research shows a mix of optimism and caution around Hansa Biopharma, with views shaped by the commercial outlook for imlifidase in kidney transplantation and autoimmune indications, as well as how quickly the company can execute on its plans.
ASKER
SEK 76.00
Asker Healthcare Group
7D
8.2%
1Y
-0.9%
MVIR
SEK 2.26
Medivir
7D
-9.3%
1Y
25.6%

Rare Disease And Liver Cancer Pipeline Will Transform Long Term Prospects

Catalysts About Medivir Medivir is a biotech company focused on developing first in class therapies in oncology and rare bone diseases, alongside partnered programs in animal health. What are the underlying business or industry changes driving this perspective?
FLERIE
SEK 27.50
Flerie
7D
-4.5%
1Y
-32.4%
SANION
SEK 15.61
Saniona
7D
-4.2%
1Y
153.8%
IMP A SDB
SEK 47.80
Implantica
7D
-1.8%
1Y
80.0%